Clik here to view.
TearLab to explore commercial partnership opportunities in Japan
TearLab (NASDAQ:TEAR; TSX:TLB) has entered into a consulting agreement with one of its directors, Dr. Adrienne Graves, who will oversee identifying and leading discussions with potential partners for...
View ArticleClik here to view.
Ciclofilin gets Japanese patent for inhibitor drugs
Closely-held Ciclofilin Pharmaceuticals has been issued a patent in Japan for its cyclophilin inhibitor drugs entitled, “Nonimmunosuppressive Cyclosporine Analogue Molecules.” The company’s lead...
View ArticleClik here to view.
ReVENT Medical prepares for U.S. pivotal trial in sleep apnea
Charlie Rampersaud Closely-held ReVENT Medical expects to begin a U.S. pivotal trial in the first half next year with its minimally invasive surgical solution to treat obstructive sleep apnea (OSA)....
View ArticleClik here to view.
In conversation with Kevin Smith
Kevin Smith As the newly appointed chief commercial officer of closely-held Sensium Healthcare, a pioneer in wireless monitoring of patient vital signs, Kevin Smith is in charge of developing and...
View ArticleClik here to view.
Can-Fite gets patent in Japan for CF101
The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine...
View ArticleClik here to view.
In conversation with Amir Ronen
Amir Ronen As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of...
View ArticleClik here to view.
Revive readies key clinical studies in gout and kidney stones
Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares. Fabio Chianelli “We...
View ArticleClik here to view.
Rodman starts BioSpecifics at buy
Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday. The company’s sole...
View ArticleClik here to view.
DiaMedica readies bridging study of DM199 protein
Rick Pauls DiaMedica (OTCQB:DMCAF; TSX-V:DMA) is preparing to begin a bridging study in the first half this year to determine the relative potency, and best dose and delivery of its lead recombinant...
View ArticleClik here to view.
Dipexium Pharma receives Locilex patent in Japan
Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry...
View ArticleClik here to view.
Merck KGaA gets approval for Juniper’s OneCrinone in Japan
Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the...
View ArticleClik here to view.
Maxim cuts Sucampo Pharma price target to $17
Maxim Group lowered its price target for Sucampo Pharmaceuticals (NASDAQ:SCMP) to $17 from $26, citing a combination of the market environment and an assessment of the catalysts and risks. The stock...
View Article
